PRAME anticorps (C-Term)
Aperçu rapide pour PRAME anticorps (C-Term) (ABIN453177)
Antigène
Voir toutes PRAME AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- This antibody reacts to MAPE.
-
Purification
- Saturated Ammonium Sulfate (SAS) precipitation
-
Immunogène
- KLH conjugated synthetic peptide selected from the C-terminal region of human MAPE
-
-
-
-
Indications d'application
-
ELISA: 1/1,000. Western blotting: 1/50 - 1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
-
Autre désignation
- PRAME / MAPE
-
Sujet
- MAPE is an antigen that is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, its gene is also expressed in acute leukemias.Synonyms: Melanoma antigen preferentially expressed in tumors, OIP-4, OIP4, OPA-interacting protein 4, Preferentially expressed antigen of melanoma
-
ID gène
- 23532
-
NCBI Accession
- NP_006106
-
UniProt
- P78395
-
Pathways
- Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding
Antigène
-